Found 16 results
Author Title [ Type(Asc)] Year
Filters: Author is Graham, BS  [Clear All Filters]
Journal Article
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 303 St, A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial, J Infect Dis, vol. 203, pp. 1396-1404, 2011.
J. E. Martin, Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B., Andrews, C., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 301 St, A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial, Vaccine, vol. 26, pp. 6338-6343, 2008.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., Graham, B. S., and Team, T. V. R. C. 201/20, Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals, Vaccine, vol. 25, pp. 1513-1525, 2007.
J. E. Ledgerwood, Costner, P., Desai, N., Holman, L., Enama, M. E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C. A., Sheets, R. A., Koup, R. A., Roederer, M., Bailer, R., ,, Pau, M. G., Sullivan, N. J., Goudsmit, J., Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 205 St, A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP is Safe and Immunogenic in Healthy Adults, Vaccine, vol. 29, pp. 304-313, 2010.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 310 St, Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect, J Infect Dis, vol. 208, pp. 418-422, 2013.
M. J. McElrath, Corey, L., Montefiori, D., Wolff, M., Schwartz, D., Keefer, M., Belshe, R., Graham, B. S., Matthews, T., Wright, P., Gorse, G., Dolin, R., Berman, P., Francis, D., Duliege, A. M., Bolognesi, D., Stablein, D., Ketter, N., Fast, P., and Grou, theA. I. D. S. Vacci, A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection, AIDS Res HumRetroviruses, vol. 16, pp. 907-19, 2000.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L., Bailer, R. T., Roederer, M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 011 St, Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (i.m.), Subcutaneous (s.c.) and Intradermal (i.d.) Administration (VRC 011), PLoS ONE, vol. 9, p. e91366, 2014.
A. T. Catanzaro, Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M. C., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 007 St, Phase I Clinical Evaluation of a Six-Plasmid Multiclade HIV-1 DNA Candidate Vaccine, Vaccine, vol. 25, pp. 4085-4092, 2007.
B. S. Graham, Koup, R. A., Roederer, M., Bailer, R., Enama, M., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K., Lamoreaux, L., Andrews, C. A., Gomez, P. L., ,, Nabel, G. J., and Team, T. Vaccine Re, Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine, J Infect Dis, vol. 194, pp. 1650-1660, 2006.
M. L. Clements-Mann, Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R. H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., and Walker, M., Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults, J Infec Dis, vol. 177, pp. 1230-46, 1998.
U. N. Sarwar, Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M. C., Bailer, R. T., McDermott, A. B., Roederer, M., ,, Ledgerwood, J. E., Graham, B. S., and Team, T. V. R. C. 015 St, Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses Despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial, PLoS One, vol. 9, p. e106240, 2014.
B. S. Graham, Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., ,, Bailer, R. T., Roederer, M., Koup, R. A., Nabel, G. J., and Team, T. V. R. C. 008 St, DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-cell Responses After rAd5 Boost in a Randomized Clinical Trial, PLoS One, vol. 8, p. e59340, 2013.
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., Graham, B. S., and Team, andThe V. R. C. 70, DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial, PLoS One, vol. 10, p. e0125914, 2015.
J. E. Ledgerwood, Wei, C. J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 306 St, DNA Priming and Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials, Lancet Infect Dis, vol. 11, pp. 916-924, 2011.
T. G. Evans, Keefer, M. C., Weinhold, K. J., Wolff, M., Montefiori, D., Gorse, G. J., Graham, B. S., McElrath, M. J., Clements-Mann, M. L., Mulligan, M. J., Fast, P., Walker, M. C., Excler, J. L., Duliege, A. M., Tartaglia, J., and Group, theN. I. A. I. D. A. I. D. S., A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers, J Infec Dis, vol. 180, pp. 290-8, 1999.
B. S. Graham, McElrath, M. J., Connor, R. I., Schwartz, D. H., Gorse, G. J., Keefer, M. C., Mulligan, M. J., Matthews, T. J., Wolinsky, S. M., Montefiori, D. C., Vermund, S. H., Lambert, J. S., Corey, L., Belshe, R. B., Dolin, R., Wright, P. F., Korber, B. T., Wolff, M. C., Fast, P., and , Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines, J Infec Dis, vol. 177, pp. 310-319, 1998.